Contributed Commentary by Hans van Leeuwen
October 29, 2026 | Every major pharma organization I’ve come across in recent years has its own version of the same AI-based ambition. It is looking to use the technology to compress the R&D timeline, reduce late-stage attrition, and make regulatory submissions faster and inspections less ...